Pharmaceutical giant AbbVie has weathered the COVID-19 storm relatively well, with its first-quarter revenue and earnings per share both coming in ahead of analyst estimates. At the same time, however, there is concern over the fact that international sales of its flagship product, Humira, are taking a serious hit. So is AbbVie, with its juicy dividend, a stock to love or leave right now? CLICK HERE.
